Kanwal Raghav Selected Research

Kanwal Raghav Research Topics

Disease

22	Neoplasms (Cancer) 01/2024 - 05/2014
21	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 01/2017
7	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 05/2014
6	Neoplasm Metastasis (Metastasis) 02/2023 - 01/2016
5	Adenocarcinoma 09/2023 - 01/2017
3	Cholangiocarcinoma 01/2024 - 10/2018
2	Residual Neoplasm 10/2022 - 12/2020
2	Mesothelioma 11/2021 - 01/2021
2	Thrombosis (Thrombus) 01/2021 - 06/2017
1	Triple Negative Breast Neoplasms 01/2024
1	Breast Neoplasms (Breast Cancer) 01/2024
1	Prostatic Neoplasms (Prostate Cancer) 01/2024
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 02/2023
1	Appendiceal Neoplasms (Appendix Cancer) 02/2023
1	Microsatellite Instability 11/2022
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Disease Progression 01/2021
1	Rectal Neoplasms (Rectal Cancer) 12/2020
1	End Stage Liver Disease 01/2020
1	Colonic Neoplasms (Colon Cancer) 01/2019
1	Stomach Neoplasms (Stomach Cancer) 01/2019
1	Portal Hypertension 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2018
1	Carcinogenesis 12/2017
1	Liver Diseases (Liver Disease) 10/2017
1	Fibrosis (Cirrhosis) 01/2017
1	Neoplasms, Cystic, Mucinous, and Serous 01/2017
1	Brain Diseases (Brain Disorder) 05/2014
1	Ascites 05/2014

Drug/Important Bio-Agent (IBA)

6	Biomarkers (Surrogate Marker)IBA 09/2023 - 08/2017
5	Immune Checkpoint InhibitorsIBA 11/2022 - 11/2020
3	Circulating Tumor DNAIBA 01/2023 - 01/2022
3	Bevacizumab (Avastin)FDA Link 11/2021 - 05/2017
2	Tumor Biomarkers (Tumor Markers)IBA 09/2023 - 01/2017
2	MucinsIBA 02/2023 - 01/2017
2	trastuzumab deruxtecanIBA 01/2023 - 01/2021
2	Cetuximab (Erbitux)FDA Link 01/2023 - 08/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 11/2021
2	durvalumabIBA 01/2022 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2017
2	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 01/2019
2	human ERBB2 proteinIBA 11/2020 - 01/2019
2	ErbB Receptors (EGF Receptor)IBA 12/2019 - 01/2018
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2018 - 05/2017
2	Cytidine Triphosphate (CTP)IBA 08/2015 - 05/2014
1	Phosphotransferases (Kinase)IBA 01/2024
1	Janus Kinase 1IBA 01/2024
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2024
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2024
1	Hormones (Hormone)IBA 01/2024
1	trifluridine tipiracil drug combinationIBA 02/2023
1	regorafenibIBA 02/2023
1	zanidatamabIBA 12/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2022
1	Gemcitabine FDA Link 01/2022
1	trametinibIBA 01/2022
1	RamucirumabIBA 01/2022
1	atezolizumabIBA 11/2021
1	Protons (Proton)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	tremelimumabIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Topoisomerase I InhibitorsIBA 01/2021
1	Insulin-Like PeptidesIBA 01/2020
1	Anti-Idiotypic AntibodiesIBA 12/2019
1	Pregnenolone Carbonitrile (PCN)IBA 01/2019
1	Angiopoietin-2IBA 12/2018
1	Angiopoietin-1IBA 12/2018
1	Panitumumab (Vectibix)FDA Link 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	taxaneIBA 01/2018
1	ProteomeIBA 12/2017
1	CollagenIBA 12/2017
1	PaxillinIBA 08/2017
1	src-Family KinasesIBA 08/2017
1	Dasatinib (BMS 354825)FDA Link 08/2017
1	Capecitabine (Xeloda)FDA Link 05/2017
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2017
1	Uridine Monophosphate (UMP)IBA 01/2017
1	Carcinoembryonic AntigenIBA 01/2017
1	AntigensIBA 01/2017
1	Calcibiotic Root Canal SealerIBA 01/2017
1	Cell-Free Nucleic AcidsIBA 01/2017
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2016
1	Insulin-Like Growth Factor I (IGF-1)IBA 05/2014
1	Insulin (Novolin)FDA Link 05/2014

Therapy/Procedure

21	Therapeutics 02/2023 - 05/2014
8	Drug Therapy (Chemotherapy) 02/2023 - 01/2017
4	Radiotherapy 12/2021 - 06/2017
3	Immunotherapy 02/2023 - 11/2020
2	Cytoreduction Surgical Procedures 02/2023 - 01/2017
2	Proton Therapy 01/2021 - 01/2019
1	Hyperthermic Intraperitoneal Chemotherapy 02/2023
1	Transplantation 01/2020